+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Translational Research Program

Jeffrey Modell Foundation

Purpose

To support innovative and novel investigations in Primary Immunodeficiency focusing on translational research leading to meaningful clinical application.
To advance the growing knowledge of genotype-phenotype correlations and gain a better understanding of the underlying mechanisms of immune function and dysfunction.
To support research that will lead to advancement in clinical recognition, diagnostic tools, and innovative therapies that will impact overall health outcomes and improve the quality of life of those affected by Primary Immunodeficiency.

To date, over 550 specific genetic defects have been identified, which have not only helped advance new therapies, but have also been instrumental in advancing our understanding of immunology. It is estimated that as many as 10 million people, if not more, are living with Primary Immunodeficiency worldwide. As such, it is crucial to support research that will bridge basic scientific discoveries to the development of clinical applications that will impact overall health outcomes. Advancing research that enhances our understanding of the immune system represents one of the single greatest strategies that biomedical science has to offer to identify new therapies and will greatly benefit those living with diagnosed Primary Immunodeficiencies as well as the millions of people that remain undiagnosed.

Award Information

The number of awards per cycle will be dependent on the strength and merit of applications received and the availability of funds. Individual awards may total up to $250,000 over a two-year period. Funds are not to exceed $125,000 per year per project. Total funds will only support direct costs and cannot be used for institutional overhead. JMF reserves the right to reduce the award amount for any application. To date, a total of 26 grants have been awarded throughout 13 grant cycles.

Application Deadlines

Cycle 14 Start Date - January 19, 2026
Letter of Intent Deadline - March 13, 2026
Full Application Deadline (for invited investigators) - July 24, 2026
Grant Awards - By December 1, 2026

Application Process and Required Materials:

There is a two-step application process. A letter of intent (LOI) is required and must be submitted in advance of a full grant application.

Note: application materials must meet the requirements below. Any applications that exceed the page limits may not be considered.

Letter of Intent

A Letter of Intent (LOI) must be submitted through ProposalCentral by March 13, 2026, separate from and prior to the full application.

The LOI form can be accessed on ProposalCentral: Access LOI Form
For instructions on how to register as a ProposalCentral user: View Registration Guide

Investigators will be notified by June 1, 2026 as to whether they've been invited to submit a full grant application.

Application

Investigators who have submitted an LOI and have been invited by the JMCN Research Committee to submit a full grant application will be considered for funding. Detailed instructions on how to submit a full application through ProposalCentral will be provided at the time of invitation.

Note: an invitation to submit a full grant application does not guarantee funding.

Application materials will include:

Application Form

Completion of all sections of ProposalCentral Application Form.

Research Proposal

A detailed Research Proposal outlining the specific aims, background, purpose, and goals of the intended project, not to exceed 6 pages. Tables, figures, and graphs, etc. may also be attached as supplemental documentation to support the 6-page proposal.

Curriculum Vitae or Biosketch

A current Curriculum Vitae or Biosketch, highlighting experience as it relates to your proposed project. Please list publications in order of relevance to the proposal. Please try not to exceed 5 pages.

Note: The materials listed above are the minimum required application materials. Additional documentation, such as letters of support, may also be included.

AI Based Application Success Predictor

JMF does not publish a formal “success predictor” or quantitative scoring rubric like some government funders, but from available program guidelines and award descriptions, several implicit predictors of success emerge:

🔍 Scientific Quality & Innovation

Research proposals that aim to advance clinical recognition, diagnostic tools, or therapies are prioritized.

🌍 Alignment With Mission

Projects must clearly address aspects of primary immunodeficiency, whether through translational research, genetic mechanisms, education, or global advocacy.

👩‍🔬 Investigator Expertise

Strong track records of productivity and relevance to PI research likely improve competitiveness, even if detailed criteria are not publicly listed.

🤝 Program Relevance & Impact

Grants that have potential to translate to clinical benefit or widespread adoption (e.g., improved diagnosis or treatment frameworks) align with the Foundation’s mission.

🌟 Collaborative or Network Value

Use of established networks (such as the Global PI Centers Network) or partnerships in proposal development may enhance prospects, though specific weighting is not published.

📌 Summary

The Jeffrey Modell Foundation funds PI research, clinical translation, education, advocacy, and community support programs globally.

Research funding includes translational research awards, specific defect research, educational grants, and global network support, with award amounts up to several hundred thousand dollars.

Formal “grant success predictors” are not publicly published, but strong scientific merit, relevance to PI, innovation, and alignment with the Foundation’s mission are implicit factors that influence success.

Specialties

Immunology

Eligibility Requirements

Grants with the following focus will be strongly considered for awards:

Novel Primary Immunodeficiency defects
Innovative approaches to early diagnosis - Novel therapeutic strategies
Translational impact on patient health (i.e., how a patient will benefit)
Reach of the proposed project (i.e., how many patients might benefit)
Projects that currently do not have funding and would be otherwise difficult to advance without this award

The Jeffrey Modell Foundation encourages all international and U.S. investigators with the appropriate knowledge and research skill level to apply for this grant. Applications submitted by investigators with vast expertise in Primary Immunodeficiency, as well as young investigators with robust scientific merit will be considered. JMF encourages investigators who are not currently receiving funding from the National Institutes of Health to apply. Only one active grant per investigator is permitted at a time. See the list of historic award recipients and proposal titles here.

All applications will be comprehensively reviewed and evaluated by the Jeffrey Modell Centers Network Peer Review Research Committee. The committee will provide an impact score for individual applications based on:

Innovation
Originality
Feasibility
Justification of requested budget
Translational applicability
Relevance to Primary Immunodeficiency
Relevance to advancement of the work

Sponsor Details

Sponsor Institute/Organizations: Jeffrey Modell Foundation

Sponsor Type: Corporate/Non-Profit

Address: 780 Third Avenue, 47th Floor New York, NY 10017 Fax: 212-764-4180

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity